s
NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson’s Disease Patients with Motor Fluctuations
18-03-2024, 14:10
REHOVOT, Israel, March 18, 2024 /PRNewswire/ — NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210). Results from the trial, which evaluated the efficacy, safety and tolerability of investigational ND0612 – a continuous, 24 hours/day subcutaneous […] L'articolo NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson’s Disease Patients with Motor Fluctuations proviene da La Ragione.
CONTINUA A LEGGERE
10
0
0
Guarda anche
La Ragione
22:12
Le Pen: “La marea cresce, la nostra vittoria è solo rimandata”
La Ragione
19:43
Keys si fa male e si ritira, Paolini ai quarti di Wimbledon
La Ragione
19:34
Domina, poi soffre, ma vince in tre set: Sinner ai quarti
La Ragione
19:06